This product is compounded tirzepatide — not Mounjaro® or Zepbound®. Prepared by a licensed compounding pharmacy. Not FDA-approved. Prescription required. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.

Dual GLP-1 + GIP Agonist · Compounded

Every other GLP-1 hits one receptor. Tirzepatide hits two.

Tirzepatide is a dual GLP-1 + GIP agonist — the first medication to activate two separate metabolic pathways simultaneously. While semaglutide targets only the GLP-1 receptor, tirzepatide's dual mechanism produces more comprehensive effects on insulin signaling, appetite regulation, and fat metabolism.

Published clinical research has demonstrated greater weight reduction than any single-receptor GLP-1 therapy in the published literature. Beyond weight management, tirzepatide has shown significant improvements in obstructive sleep apnea severity — a finding the FDA recognized with a second approved indication for the molecule in 2024.

At Obsidian Genetics, we offer physician-supervised compounded tirzepatide — personalized dosing, flat monthly pricing, and a clinical team in your corner.

Prescription required · Free shipping
Tirzepatide Injection vial
Tirzepatide Injection
At Obsidian Genetics, we offer physician-supervised compounded tirzepatide — personalized dosing, flat monthly pricing, and ongoing provider support built in.
$199.00

Includes Ongoing Provider Care & Support
Syringes & Alcohol Pads Kit · Platform Access & Educational Content

🛡️100% Online
🩺Board-Certified
📦Fast Shipping
Pricing

Simple, transparent pricing.

One flat monthly rate — your dose is personalized by your physician at no extra charge.

1 Month
$199 / mo

Get started with full physician support, supplies, and clinical access included.

3 Months
$163 / mo

Commit to your first quarter. Most patients see significant results by week 12.

6 Months
$155 / mo

Reach your target dose and experience the full metabolic benefit.

Best Value
12 Months
$145 / mo

Maximum results, minimum cost. The most popular plan for long-term transformation.

Every plan includes:  Compounded tirzepatide · Syringes & alcohol pads · Physician consultation · Ongoing provider support · Platform & educational access
Clinical Trial Results

The numbers that change the conversation.

Tirzepatide has produced the most significant weight loss results ever recorded in a randomized clinical trial.

22.5%
Average body weight lost SURMOUNT-1, highest dose group, 72 weeks
47%
More weight lost vs. semaglutide SURMOUNT-5 head-to-head trial, 2025
91%
Achieved ≥5% body weight loss SURMOUNT-1, 15 mg dose, 72 weeks
57%
Achieved ≥20% body weight loss SURMOUNT-1, 15 mg dose, 72 weeks
SURMOUNT-1 — Jastreboff et al., NEJM 2022  |  SURMOUNT-5 — Aronne et al., NEJM 2025 — head-to-head tirzepatide vs. semaglutide 2.4mg

Individual results vary. Clinical outcomes cited reflect trials conducted on FDA-approved branded tirzepatide formulations. Compounded tirzepatide contains the same active ingredient prepared by a licensed compounding pharmacy, but has not undergone independent clinical trials and is not FDA-approved.

Clinical Applications

What tirzepatide is prescribed for.

→ Weight loss & body composition FDA Approved
→ Metabolic health & insulin sensitivity FDA Approved
→ Sleep apnea FDA Approved
→ Cardiovascular risk reduction Research Supported
→ Blood sugar & appetite regulation Research Supported
→ Fatty liver disease (NAFLD/NASH) Research Supported
→ PCOS & hormonal weight gain Emerging Research
→ Inflammation reduction & longevity support Emerging Research

*FDA approvals refer to the branded tirzepatide molecule (Zepbound®). Compounded tirzepatide is not FDA-approved.

[ Active / healthy lifestyle image ]
What You Get

Everything you need. Nothing you don't.

01

Compounded Tirzepatide

Physician-prescribed and dispensed from a licensed 503B compounding pharmacy. Dose titrated to your response.

02

Injection Supplies

Syringes and alcohol prep pads included with every shipment.

03

Board-Certified Physician Review

Your health history is reviewed by a licensed provider who determines the right starting dose for you.

04

Ongoing Clinical Support

Your provider monitors your progress and adjusts your dose at no additional cost. No surprise charges.

05

Platform & Educational Content

Access to your patient portal, dosing guides, and the Obsidian Genetics clinical support team.

[ Product kit / vial + syringe flat lay image ]
The Science

Why two receptors changes everything.

Mechanism 01

GLP-1 Receptor Activation

Like semaglutide, tirzepatide activates the GLP-1 receptor — reducing appetite, slowing gastric emptying, and improving insulin response. This alone drives significant weight loss.

Mechanism 02

GIP Receptor Activation

Unlike any other approved GLP-1 therapy, tirzepatide also activates the GIP receptor. GIP enhances fat burning, reduces GLP-1 side effects, and provides additional metabolic benefits.

Combined Effect

The Dual Advantage

The dual-agonist mechanism produces weight loss outcomes no single-receptor GLP-1 has achieved. Two separate satiety signals. Two separate metabolic drivers. Measurably different results.

Tirzepatide vs. Semaglutide.
The head-to-head data.

In the 2025 SURMOUNT-5 trial — the first direct comparison of its kind — tirzepatide was tested head-to-head against semaglutide 2.4mg in people with obesity. Tirzepatide won. By a significant margin.

47%
More weight lost Tirzepatide vs. semaglutide 2.4mg · SURMOUNT-5, 2025
2×
Receptor targets GLP-1 + GIP vs. GLP-1 only
22.5%
Average body weight lost SURMOUNT-1 — the highest recorded in any GLP-1 trial
Important Information

Safety & Considerations

Tirzepatide is a prescription medication. Your Obsidian Genetics provider will review your full health history before prescribing.

Gastrointestinal Effects

Nausea, vomiting, and diarrhea are most common during dose escalation. These typically resolve as your body adjusts. Your provider will titrate your dose gradually to minimize discomfort.

Hypoglycemia Risk

Low blood sugar is a rare risk with tirzepatide alone, but increases when combined with insulin or sulfonylureas. Your provider will account for any concurrent medications before prescribing.

Injection Site Reactions

Mild redness or discomfort at the injection site may occur. Rotating injection sites and using proper technique (detailed in your dosing guide) minimizes this risk.

⚠ Important Contraindications

Do not use tirzepatide if you or a family member have a personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Animal studies have shown a potential association between GLP-1 receptor agonists and thyroid tumors — the risk to humans is not fully established. Tirzepatide is also not recommended if you have a personal history of pancreatitis. Disclose your full medical history during your intake consultation. A prescription will only be issued if your provider determines tirzepatide is appropriate for you.

Questions

Frequently asked questions.

Semaglutide is a GLP-1 receptor agonist — it targets one metabolic receptor. Tirzepatide is a dual GLP-1 + GIP agonist — it targets two. The GIP receptor activation provides additional appetite suppression, enhanced fat metabolism, and may reduce the nausea commonly associated with GLP-1-only therapies. In a 2025 head-to-head trial (SURMOUNT-5), tirzepatide produced 47% more weight loss than semaglutide 2.4mg.
In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. 91% achieved at least 5% weight loss, and 57% achieved at least 20% weight loss at the 15 mg dose. Individual results vary based on starting weight, dose, adherence, and lifestyle. Your provider will set realistic expectations during your consultation.
Compounded tirzepatide is tirzepatide prepared by a licensed 503B outsourcing facility — a federally regulated compounding pharmacy. It contains the same active ingredient as Mounjaro® and Zepbound® but is not manufactured by Eli Lilly. Compounded medications are not FDA-approved; however, they are legally prescribed and dispensed when produced by a licensed, regulated facility. All Obsidian Genetics medications come from licensed, inspected compounding pharmacies.
Tirzepatide is administered as a once-weekly subcutaneous injection (just under the skin). Common injection sites include the abdomen, thigh, or upper arm. Your plan includes syringes, alcohol prep pads, and a detailed dosing guide. Most patients find the injection simple and quick after the first few weeks.
Yes, tirzepatide is typically started at a low dose and titrated upward over several weeks to minimize side effects. Your provider manages this process. At Obsidian Genetics, your monthly price stays the same regardless of dose — we charge a flat rate based on the medication, not the dose level. No surprise charges.
Many patients transition from semaglutide to tirzepatide to achieve greater results. Your provider will review your current dose and history during the intake process. If a switch is appropriate, they'll coordinate a dosing plan that accounts for your existing tolerance and minimizes side effects from the transition.
Store tirzepatide in the refrigerator between 36°F and 46°F (2°C–8°C). Do not freeze. Keep out of direct sunlight. If your medication has been left at room temperature, contact your provider before using. Detailed storage instructions are included with each shipment.

Prescription Required. Tirzepatide is a prescription medication. A valid prescription from a licensed healthcare provider is required before any medication is dispensed. Obsidian Genetics facilitates access to board-certified physicians who independently determine whether treatment is appropriate for each patient. We do not guarantee that a prescription will be issued.

Compounded Medication Notice. This product is compounded tirzepatide prepared by a licensed 503B outsourcing facility. Compounded medications are not FDA-approved. Their safety and effectiveness have not been independently verified by the FDA. Compounded tirzepatide is not Mounjaro® or Zepbound®, and Obsidian Genetics is not affiliated with Eli Lilly and Company.

Trademark Notices. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. These brand names are referenced for informational purposes only.

Results Disclaimer. Individual results vary. Clinical trial outcomes referenced on this page represent results from controlled research studies and may not reflect results for every patient. Weight loss results depend on individual factors including starting weight, dose adherence, diet, activity level, and overall health status.

Not Medical Advice. The information on this page is for educational purposes only and does not constitute medical advice. Consult your provider with any questions about your health or treatment plan.